Biocon Biologics has entered into a long-term commercial collaboration deal with pharma company Eris Lifesciences that features the sale of Biocon’s metabolics, oncology, and critical care products in the Indian market, for a total transaction value of INR12.4bn ($149m).
Over 430 Biocon employees will be moved to Eris as part of the portfolio transfer. The deal, which is expected...






